153 related articles for article (PubMed ID: 35941241)
1. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.
Miszczuk M; Chapiro J; Do Minh D; van Breugel JMM; Smolka S; Rexha I; Tegel B; Lin M; Savic LJ; Hong K; Georgiades C; Nezami N
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1494-1502. PubMed ID: 35941241
[TBL] [Abstract][Full Text] [Related]
2. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
[TBL] [Abstract][Full Text] [Related]
3. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
[TBL] [Abstract][Full Text] [Related]
4. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
7. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.
Gowdra Halappa V; Corona-Villalobos CP; Bonekamp S; Li Z; Reyes D; Cosgrove D; Pawlik TM; Diaz LA; Bhagat N; Eng J; Geschwind JF; Kamel IR
Radiology; 2013 Feb; 266(2):502-13. PubMed ID: 23192780
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
11. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
[TBL] [Abstract][Full Text] [Related]
12. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
14. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
[TBL] [Abstract][Full Text] [Related]
15. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis.
Kress O; Wagner HJ; Wied M; Klose KJ; Arnold R; Alfke H
Digestion; 2003; 68(2-3):94-101. PubMed ID: 14593235
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.
Lin M; Pellerin O; Bhagat N; Rao PP; Loffroy R; Ardon R; Mory B; Reyes DK; Geschwind JF
J Vasc Interv Radiol; 2012 Dec; 23(12):1629-37. PubMed ID: 23177109
[TBL] [Abstract][Full Text] [Related]
18. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
19. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT.
Schernthaner RE; Haroun RR; Duran R; Lee H; Sahu S; Sohn JH; Chapiro J; Zhao Y; Gorodetski B; Fleckenstein F; Smolka S; Radaelli A; van der Bom IM; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1429-37. PubMed ID: 27380872
[TBL] [Abstract][Full Text] [Related]
20. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]